CREO vs. EKF, IUG, NCYT, IHC, POLX, AVO, RUA, SUN, MHC, and BELL
Should you be buying Creo Medical Group stock or one of its competitors? The main competitors of Creo Medical Group include EKF Diagnostics (EKF), Intelligent Ultrasound Group (IUG), Novacyt (NCYT), Inspiration Healthcare Group (IHC), Polarean Imaging (POLX), Advanced Oncotherapy (AVO), RUA Life Sciences (RUA), Surgical Innovations Group (SUN), MyHealthChecked (MHC), and Belluscura (BELL). These companies are all part of the "medical devices" industry.
Creo Medical Group vs. Its Competitors
Creo Medical Group (LON:CREO) and EKF Diagnostics (LON:EKF) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.
EKF Diagnostics has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.
45.1% of Creo Medical Group shares are held by institutional investors. Comparatively, 50.0% of EKF Diagnostics shares are held by institutional investors. 4.1% of Creo Medical Group shares are held by insiders. Comparatively, 39.4% of EKF Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
EKF Diagnostics has a net margin of 9.37% compared to Creo Medical Group's net margin of -73.93%. EKF Diagnostics' return on equity of 7.03% beat Creo Medical Group's return on equity.
In the previous week, Creo Medical Group and Creo Medical Group both had 1 articles in the media. Creo Medical Group's average media sentiment score of 0.75 beat EKF Diagnostics' score of 0.67 indicating that Creo Medical Group is being referred to more favorably in the media.
Creo Medical Group has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, EKF Diagnostics has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500.
Summary
EKF Diagnostics beats Creo Medical Group on 9 of the 12 factors compared between the two stocks.
Get Creo Medical Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for CREO and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Creo Medical Group Competitors List
Related Companies and Tools
This page (LON:CREO) was last updated on 9/13/2025 by MarketBeat.com Staff
Free CREO Stock Alerts